NCT04987788

Brief Summary

Among Latinos, a fast growing and underserved population, Colorectal Cancer (CRC) is the third leading cause of cancer death in men and in women. Compared to non-Latino whites, Latinos are less likely to be diagnosed with localized CRC and more likely to be diagnosed with advanced stage disease. Of the recommended CRC screening tests, a colonoscopy allows for both the detection and removal of precancerous and cancerous polyps. Although screening colonoscopies can detect and prevent CRC, more than half of Latinos have not received a screening colonoscopy within the recommended time frame (one screening colonoscopy per ten years). The purpose of this study is to develop and begin to test an electronically-delivered motivational interviewing progressive web application (e-MI app), called Motívate. The Motívate app will be offered in both English and Spanish to patients who self-identify as Latino/a/x, after they receive a referral for a screening colonoscopy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at below P25 for not_applicable colorectal-cancer

Timeline
Completed

Started Aug 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 23, 2021

Completed
11 days until next milestone

First Posted

Study publicly available on registry

August 3, 2021

Completed
16 days until next milestone

Study Start

First participant enrolled

August 19, 2021

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 27, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 27, 2023

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

June 18, 2024

Completed
Last Updated

June 18, 2024

Status Verified

May 1, 2024

Enrollment Period

1.7 years

First QC Date

July 23, 2021

Results QC Date

April 23, 2024

Last Update Submit

May 24, 2024

Conditions

Keywords

ColonoscopyEarly Detection of CancerCancer Screening TestsMotivational InterviewingMobile HealthColorectal Cancer

Outcome Measures

Primary Outcomes (1)

  • Colonoscopy Completion

    Screening colonoscopy completion status in medical charts six months after participants are enrolled in the study.

    Six months after enrollment

Study Arms (2)

Motívate group

EXPERIMENTAL

Participants will engage with an app on an iPad, smartphone or computer.

Behavioral: Motívate

Control Group

ACTIVE COMPARATOR

Participant receive a link to watch a general health information video.

Behavioral: Video link

Interventions

MotívateBEHAVIORAL

The Motívate app can be used in English or Spanish and involves four sequential phases. 1) The engaging phase uses videos to welcome participants. 2) Patients willing to discuss the decision to have a screening colonoscopy will answer multiple-choice questions on colorectal cancer prevention - completing the focusing phase. Optional videos will offer additional information. 3) The evoking phase consists of interactive Motivational Interviewing exercises to help participants elicit motivations to get a screening colonoscopy. 4) During the planning phase, participants will view a video that will discuss the steps needed to prepare for the colonoscopy.

Motívate group
Video linkBEHAVIORAL

General health information video link

Control Group

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Self-identified as Latino/a/x;
  • English or Spanish-speaking;
  • Received a physician referral for a screening colonoscopy;
  • Has access to a tablet, smartphone, or computer with working Internet.

You may not qualify if:

  • Hearing or vision impaired;
  • Aim 1 or 2 participant.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

Location

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Results Point of Contact

Title
Sarah Miller
Organization
Icahn School of Medicine at Mount Sinai

Study Officials

  • Sarah J. Miller, PsyD

    Icahn School of Medicine at Mount Sinai

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

July 23, 2021

First Posted

August 3, 2021

Study Start

August 19, 2021

Primary Completion

April 27, 2023

Study Completion

April 27, 2023

Last Updated

June 18, 2024

Results First Posted

June 18, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will share

All of the individual participant data collected during the trial, after deidentification.

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Immediately following publication. No end date.
Access Criteria
Researchers who provide a methodologically sound proposal. Any purpose. Proposals should be directed to sarah.miller@mssm.edu. To gain access, data requestors will need to sign a data access agreement. Upon request, we will provide the de-identified dataset to qualified investigators under a Data Use Agreement that provides for: 1) a commitment to using the data only for research purposes; (2) a commitment to securing the data using appropriate computer technology; and, (3) a commitment to destroying or returning the data after analyses are completed.

Locations